1 Collaborators, G. B. D. C. o. D. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1736-1788, doi:10.1016/S0140-6736(18)32203-7 (2018).
2 Global Burden of Disease Liver Cancer, C. et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol 3, 1683-1691, doi:10.1001/jamaoncol.2017.3055 (2017).
3 European Association for the Study of the Liver. Electronic address, e. e. e. & European Association for the Study of the, L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69, 182-236, doi:10.1016/j.jhep.2018.03.019 (2018).
4 Ganne-Carrie, N. & Nahon, P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol 70, 284-293, doi:10.1016/j.jhep.2018.10.008 (2019).
5 Hagstrom, H. et al. Risk of Cancer in Biopsy-Proven Alcohol-Related Liver Disease: A Population-Based Cohort Study of 3410 Persons. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, doi:10.1016/j.cgh.2021.01.005 (2021).
6 Joshi, K., Kohli, A., Manch, R. & Gish, R. Alcoholic Liver Disease: High Risk or Low Risk for Developing Hepatocellular Carcinoma? Clin Liver Dis 20, 563-580, doi:10.1016/j.cld.2016.02.012 (2016).
7 Mancebo, A. et al. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 11, 95-101, doi:10.1016/j.cgh.2012.09.007 (2013).
8 Peter Jepsen, M., PhD; Peter Ott, MD, DMSc; Per Kragh Andersen, PhD, DMSc; Henrik Toft Sørensen, MD, PhD, DMSc; and Hendrik Vilstrup, MD, DSc. Risk for Hepatocellular Carcinoma in Patients With Alcoholic Cirrhosis. Ann Intern Med. 156 (2012).
9 Ganne-Carrie, N. et al. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J Hepatol 69, 1274-1283, doi:10.1016/j.jhep.2018.07.022 (2018).
10 Jepsen, P. et al. Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis. J Hepatol 73, 1030-1036, doi:10.1016/j.jhep.2020.05.043 (2020).
11 Wu, S. et al. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, doi:10.1016/j.cgh.2021.02.040 (2021).
12 Flemming, J. A., Yang, J. D., Vittinghoff, E., Kim, W. R. & Terrault, N. A. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer 120, 3485-3493, doi:10.1002/cncr.28832 (2014).
13 Sharma, S. A. et al. Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. J Hepatol, doi:10.1016/j.jhep.2017.07.033 (2017).
14 Ioannou, G. N., Green, P., Kerr, K. F. & Berry, K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol 71, 523-533, doi:10.1016/j.jhep.2019.05.008 (2019).
15 Matsushita, H. & Takaki, A. Alcohol and hepatocellular carcinoma. BMJ Open Gastroenterol 6, e000260, doi:10.1136/bmjgast-2018-000260 (2019).
16 Yim, S. Y. & Kim, J. H. The epidemiology of hepatitis B virus infection in Korea. Korean J Intern Med 34, 945-953, doi:10.3904/kjim.2019.007 (2019).
17 Kwon, G. Y. et al. Regional distribution of hepatitis C virus infection in the Republic of Korea, 2007-2011. Gut Liver 8, 428-432, doi:10.5009/gnl.2014.8.4.428 (2014).
18 Jeong, S. H. et al. Current status of hepatitis C virus infection and countermeasures in South Korea. Epidemiol Health 39, e2017017, doi:10.4178/epih.e2017017 (2017).
19 Wolkewitz, M., Cooper, B. S., Bonten, M. J., Barnett, A. G. & Schumacher, M. Interpreting and comparing risks in the presence of competing events. BMJ 349, g5060, doi:10.1136/bmj.g5060 (2014).
20 Zhang, Z. et al. Overview of model validation for survival regression model with competing risks using melanoma study data. Ann Transl Med 6, 325, doi:10.21037/atm.2018.07.38 (2018).
21 Yoo, S. et al. Seoul National University Bundang Hospital's Electronic System for Total Care. Healthcare informatics research 18, 145-152, doi:10.4258/hir.2012.18.2.145 (2012).
22 Chung, J. W. et al. Optimizing Surveillance Performance of Alpha-Fetoprotein by Selection of Proper Target Population in Chronic Hepatitis B. PLoS One 11, e0168189, doi:10.1371/journal.pone.0168189 (2016).
23 Yoo, S., Hwang, H. & Jheon, S. Hospital information systems: experience at the fully digitized Seoul National University Bundang Hospital. J Thorac Dis 8, S637-641, doi:10.21037/jtd.2016.08.44 (2016).
24 Marrero, J. A. et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68, 723-750, doi:10.1002/hep.29913 (2018).
25 Heimbach, J. K. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67, 358-380, doi:10.1002/hep.29086 (2018).
26 Tang, A. et al. Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review. Radiology 286, 29-48, doi:10.1148/radiol.2017170554 (2018).
27 Fine, J. P. & Gray, R. J. A Proportional Hazards Model for the Subdistribution of a Competing Risk. Journal of the American Statistical Association 94, 496-509, doi:10.1080/01621459.1999.10474144 (1999).
28 Lambert, P. C. The estimation and modelling of cause-specific cumulative incidence functions using time-dependent weights. Stata J 17, 181-207 (2017).
29 O'Shea, R. S., Dasarathy, S., McCullough, A. J., Practice Guideline Committee of the American Association for the Study of Liver, D. & Practice Parameters Committee of the American College of, G. Alcoholic liver disease. Hepatology 51, 307-328, doi:10.1002/hep.23258 (2010).
30 D'Amico, G. et al. Clinical states of cirrhosis and competing risks. J Hepatol 68, 563-576, doi:10.1016/j.jhep.2017.10.020 (2018).
31 Jepsen, P., Vilstrup, H. & Andersen, P. K. The clinical course of cirrhosis: The importance of multistate models and competing risks analysis. Hepatology 62, 292-302, doi:10.1002/hep.27598 (2015).
32 Singal, A. K., Bataller, R., Ahn, J., Kamath, P. S. & Shah, V. H. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol 113, 175-194, doi:10.1038/ajg.2017.469 (2018).
33 Jepsen, P. & West, J. We need stronger evidence for (or against) hepatocellular carcinoma surveillance. J Hepatol 74, 1234-1239, doi:10.1016/j.jhep.2020.12.029 (2021).
34 Wang, H. W. et al. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy. J Gastroenterol Hepatol 34, 442-449, doi:10.1111/jgh.14372 (2019).
35 Na, S. K. & Song, B. C. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C. Clin Mol Hepatol 25, 234-244, doi:10.3350/cmh.2018.0108 (2019).
36 Yoo, S., Kim, S., Lee, K. H., Baek, R. M. & Hwang, H. A study of user requests regarding the fully electronic health record system at Seoul National University Bundang Hospital. Stud Health Technol Inform 192, 1015 (2013).
37 Lackner, C. et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol 66, 610-618, doi:10.1016/j.jhep.2016.11.011 (2017).
38 Shah, N. D. et al. Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 17, 2320-2329 e2312, doi:10.1016/j.cgh.2019.01.026 (2019).
39 Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43, 1317-1325, doi:10.1002/hep.21178 (2006).